Below are the most recent publications written about "Lung Neoplasms" by people in Profiles.
-
Zhao J, Barta JA, McIntire R, Shusted C, Zeigler-Johnson C, Juon HS. Racial difference in BMI and lung cancer diagnosis: analysis of the National Lung Screening Trial. BMC Cancer. 2022 Jul 19; 22(1):797.
-
Shusted CS, Evans NR, Kane GC, Juon HS, Barta JA. Analysis of Lung Cancer Screening by Race After USPSTF Expansion of Screening Eligibility in 2021. JAMA Netw Open. 2022 Jun 01; 5(6):e2217578.
-
Harel M, Lahav C, Jacob E, Dahan N, Sela I, Elon Y, Raveh Shoval S, Yahalom G, Kamer I, Zer A, Sharon O, Carbone DP, Dicker AP, Bar J, Shaked Y. Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade. J Immunother Cancer. 2022 Jun; 10(6).
-
DiCarlo M, Myers P, Daskalakis C, Shimada A, Hegarty S, Zeigler-Johnson C, Juon HS, Barta J, Myers RE. Outreach to primary care patients in lung cancer screening: A randomized controlled trial. Prev Med. 2022 Jun; 159:107069.
-
McIntire RK, Lewis E, Zeigler-Johnson C, Shusted C, Barta J, Juon HS, Keith SW, Klein G. Estimating Eligibility for Lung Cancer Screening by Neighborhood in Philadelphia Using Previous and Current USPSTF Guidelines. Popul Health Manag. 2022 04; 25(2):254-263.
-
Herskovitz E, Solomides C, Barta J, Evans N, Kane G. Detection of lung carcinoma arising from ground glass opacities (GGO) after 5 years - A retrospective review. Respir Med. 2022 05; 196:106803.
-
Schoenfeld JD, Giobbie-Hurder A, Ranasinghe S, Kao KZ, Lako A, Tsuji J, Liu Y, Brennick RC, Gentzler RD, Lee C, Hubbard J, Arnold SM, Abbruzzese JL, Jabbour SK, Uboha NV, Stephans KL, Johnson JM, Park H, Villaruz LC, Sharon E, Streicher H, Ahmed MM, Lyon H, Cibuskis C, Lennon N, Jhaveri A, Yang L, Altreuter J, Gunasti L, Weirather JL, Mak RH, Awad MM, Rodig SJ, Chen HX, Wu CJ, Monjazeb AM, Hodi FS. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2022 02; 23(2):279-291.
-
Barta JA. Variation in Adherence to Lung Cancer Screening Among Vulnerable Populations. Chest. 2022 01; 161(1):16-17.
-
Fisk JN, Mahal AR, Dornburg A, Gaffney SG, Aneja S, Contessa JN, Rimm D, Yu JB, Townsend JP. Premetastatic shifts of endogenous and exogenous mutational processes support consolidative therapy in EGFR-driven lung adenocarcinoma. Cancer Lett. 2022 02 01; 526:346-351.
-
Vinogradskiy Y, Castillo R, Castillo E, Schubert L, Jones BL, Faught A, Gaspar LE, Kwak J, Bowles DW, Waxweiler T, Dougherty JM, Gao D, Stevens C, Miften M, Kavanagh B, Grills I, Rusthoven CG, Guerrero T. Results of a Multi-Institutional Phase 2 Clinical Trial for 4DCT-Ventilation Functional Avoidance Thoracic Radiation Therapy. Int J Radiat Oncol Biol Phys. 2022 03 15; 112(4):986-995.